genOway SA

Paris Stock Exchange ALGEN.PA

genOway SA Free Cash Flow Yield on February 05, 2025: 4.38%

genOway SA Free Cash Flow Yield is 4.38% on February 05, 2025, a 6.03% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • genOway SA 52-week high Free Cash Flow Yield is 5.05% on January 22, 2025, which is 15.45% above the current Free Cash Flow Yield.
  • genOway SA 52-week low Free Cash Flow Yield is 3.64% on June 07, 2024, which is -16.87% below the current Free Cash Flow Yield.
  • genOway SA average Free Cash Flow Yield for the last 52 weeks is 4.21%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
Paris Stock Exchange: ALGEN.PA

genOway SA

CEO Dr. Alexandre Fraichard
IPO Date May 7, 2007
Location France
Headquarters Technopark 2
Employees 124
Sector Healthcare
Industries
Description

genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.

Similar companies

ALBIO.PA

Biosynex SA

USD 1.18

2.98%

ALERS.PA

Eurobio Scientific SA

USD 26.53

-0.92%

StockViz Staff

February 7, 2025

Any question? Send us an email